Use of lytics in patients with pleural empyema

Posted on by
Reply

“Parapneumonic effusions evolve through a spectrum of three stages. The initial exudative stage (stage 1; analogous to simple parapneumonic effusion) is characterised by an increased outpouring of fluid into the pleural space mediated by capillary permeability. If left
untreated, persistent inflammation with the associated rise in fluid plasminogen activator inhibitor causes a decrease in fluid fibrinolytic concentrations. During this second stage (stage 2; fibrinopurulent stage), as the effusion becomes infected, septations and adhesions
induced by fibrin deposition divide the space into pockets or locules. With the proliferation of fibroblasts and the formation of a pleural peel, lung expansion becomes restricted and can result in a non-expandable lung. It is important to initiate all medical treatment before this
final so-called organising stage (stage 3) ensues.”

Continue reading →

Management of Empyema

Posted on by
Reply

“Empyema thoracis, from the Greek, is defined as ‘‘pus in the chest.’’ The most common precursor of empyema is bacterial pneumonia and subsequent parapneumonic effusion. Other causes of empyema include bronchogenic carcinoma, esophageal rupture, blunt or penetrating chest trauma, mediastinitis with pleural extension, infected congenital cysts of the airway and esophagus, extension from sources below the diaphragm, cervical and
thoracic spine infections, as well as postsurgical etiologies.”

Continue reading →

Postoperative Inflammatory Response in Crohn’s Patients

Posted on by
Reply

“Crohn’s Disease is an inflammatory bowel disease with a multifactorial pathophysiology. Genetic, immune, gut microbiota, and other environmental factors play a role in the occurrence and maintenance of bowel inflammation. Unfortunately, despite the development of new drugs, about half of all CD patients will need surgery during their disease course.”

Continue reading →

B-SAFE landmarks

Posted on by
Reply

“The incidence of biliary injury after laparoscopic cholecystectomy (LC) has shown a declining trend though it may still be twice that as with open cholecystectomy. Major biliary or vasculobiliary injury is associated with significant morbidity. As prevention is the best strategy, the concept of a culture of safe cholecystectomy has been recently introduced to educate surgeons and apprise them of basic tenets of safe performance of LC. Various aspects of safe cholecystectomy include:
(1) thorough knowledge of relevant anatomy, various anatomical landmarks, and anatomical variations
(2) an understanding of the mechanisms involved in biliary/vascular injury, the most important being the misidentification injury
(3) identification of various preoperative and intraoperative predictors of difficult cholecystectomy
(4) proper gallbladder retraction
(5) safe use of various energy devices
(6) understanding the critical view of safety, including its doublet view and documentation
(7) awareness of various error traps (e.g., fundus first technique)
(8) use of various bailout strategies (e.g., subtotal cholecystectomy) in difficult gallbladder cases
(9) use of intraoperative imaging techniques (e.g., intraoperative cholangiogram) to ascertain correct anatomy
(10) understanding the concept of time-out.”

Continue reading →

Bismuth classification, detection, and management of Bile Duct Injury during laparoscopic cholecystectomy

Posted on by
Reply

“Bile duct injury (BDI) is a dangerous complication of cholecystectomy, with significant postoperative sequelae for the patient in terms of morbidity, mortality, and long-term quality of life. BDIs have an estimated incidence of 0.4–1.5%, but considering the number of cholecystectomies performed worldwide, mostly by laparoscopy, surgeons must be prepared to manage this surgical challenge. Most BDIs are recognized either during the procedure or in the immediate postoperative period. However, some BDIs may be discovered later during the postoperative period, and this may translate to delayed or inappropriate treatments. Providing a specific diagnosis and a precise description of the BDI will expedite the decision-making process and increase the chance of treatment success.”

Continue reading →

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

Posted on by
Reply

“While most studies have found that patients with dMMR (vs proficient MMR [pMMR]) tumors have a more favorable stage-adjusted prognosis, other studies have not detected a significant difference in clinical outcome or have suggested that any favorable prognostic effect of dMMR is limited to patients with earlier-stage tumors. Furthermore, studies have shown that dMMR tumors may not benefit from fluorouracil-based adjuvant chemotherapy. However, the impact of MMR status remains controversial in the era of the standard FOLFOX adjuvant chemotherapy.
In a pooled analysis, we examined the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX from 2 phase 3 randomized clinical trials.”

Continue reading →

Mouse study: polyphosphate administration may be an alternative approach to prevent anastomotic leak induced by collagenolytic bacteria

Posted on by
Reply

“Despite decades of descriptive research, the etiology and pathogenesis of AL remains unknown. Although there is compelling evidence that microbes are the primary drivers of the pathogenesis of anastomotic leak, few efforts have been aimed at understanding and controlling the microbes that may complicated anastomotic healing.”

“A microbial cause for anastomotic leak was first proposed over 60 years ago and has been confirmed in multiple studies. The main clinical evidence for a microbial cause of anastomotic leak is indirect and is based on clinical trials in which the use of oral non-absorbable antibiotics significantly reduce the incidence of anastomotic leak”

Continue reading →